哪里买到假厄瓜多尔居留证,【telegram:十852 55367074】（whatsApp:+852 55367074）办理哪里买到假厄瓜多尔居留证,购买哪里买到假厄瓜多尔居留证,定制哪里买到假厄瓜多尔居留证,出售哪里买到假厄瓜多尔居留证,办理哪里买到假厄瓜多尔居留证多少钱『真实办护照，可根据客户样本制版印刷』可加急 ,【telegram:+852 55367074】【WHATSApp:+852 55367074】『办理驾驶证、身份证id、居留证、各种证明，发货速度快。』 联系我们【飞机\whatsapp 同号:+852 55367074】哪里买到假厄瓜多尔居留证,哪里买到假厄瓜多尔居留证,哪里买到假厄瓜多尔居留证 Original Biological World Biological World included in the topic # Cancer Research 78 # Science News 58 Author | Nagashi Editor | Wang Cong Typesetting | Shui Chengwen Regarding the relationship between the immune system and cancer cells, we often think of cats and mice, but can all cats catch mice?Will there be some cats who like to make friends with mice and would not hesitate to become a "disgrace to the cat world"?The answer is yes, at least that's the kind of cat Tom is.So, in the human immune system, is there also a type of immune cells that cannot withstand the sugar-coated bullets from cancer cells, rebel into the enemy camp, and in turn help the enemy?On February 15, 2021, researchers from the Hillman Cancer Center and the University of Pittsburgh School of Medicine published a research paper titled: Metabolic support of tumour-infiltrating regulatory T cells by lactic acid in the top international academic journal Nature.This study shows that the tumor microenvironment can "incite" a subpopulation of immune T cells called regulatory T cells (Treg), reducing the sensitivity of cancer patients to immunotherapy.The tumor microenvironment produces lactic acid through metabolism and maintains a high lactic acid environment to inhibit T cells that attack cancer cells. At the same time, lactic acid "feeds" regulatory T cells (Treg) to protect themselves and evade the immune system.More importantly, the study also found and confirmed that inhibiting the MCT1 gene can prevent lactate uptake, thereby enhancing the efficacy of cancer immunotherapy.In recent years, the rise of immunotherapy has opened up a new era of cancer treatment and brought new hope to the majority of cancer patients.Regrettably, however, immunotherapy is not effective for everyone. For some cancer patients, especially young and female cancer patients, immunotherapy has little effect or even no effect at all.More importantly, although individual differences in immunotherapy have always existed, in fact there are many specific reasons for this phenomenon, and until now the scientific community has not been able to provide a sufficient explanation.In this regard, Dr. Greg Delgoffe, corresponding author of this study and associate professor in the Department of Immunology at the University of Pittsburgh School of Medicine, said: "Most people do not respond to immunotherapy because we do not really understand the interaction between the immune system and the tumor microenvironment." In this study, based on previous research findings that Treg cells have different metabolic characteristics from effector T cells, the research team boldly hypothesized that metabolic changes in the tumor microenvironment (TME) are related to the increase in the suppressive activity of Treg cells within the tumor.Treg cells have metabolic characteristics different from traditional T cells in normal and transplanted tumor tissues. Treg cells are an important immune T cell that can inhibit the activation and division of effector T cells that kill cancer cells, maintain tolerance to self-antigens, and prevent autoimmune diseases such as type 1 diabetes, Crohn's disease, and multiple sclerosis.Notably, tumor cells generate a metabolically depleted, hypoxic, and acidic tumor microenvironment that can attract Treg cells and promote their functional specialization.Therefore, effector T cells entering tumor tissue will face the situation of being "enemies from both sides" - not only competing with tumor cells for metabolites, but also being strongly suppressed by Treg cells in the tumor microenvironment.In in vitro cell culture experiments, the researchers found that when Treg cells used the glycolytic pathway (the glycolytic pathway does not require oxygen and produces lactic acid by-products) to metabolize glucose in high-sugar culture media, the Treg cells became unstable and had a poor ability to suppress effector T cells.Glucophilia is associated with reduced Treg cell function. However, unlike most other cells, Treg cells are able to tolerate high levels of lactate.The research team found that when treated with lactic acid, the state of Treg cells in high-glucose medium steadily improved and resumed growth and division.Coincidentally, tumor cells usually use the glycolytic pathway to generate energy and produce large amounts of lactic acid.From this point of view, tumor cells and Treg cells are a natural match. Tumor cells produce lactic acid to feed Treg cells, while Treg cells inhibit effector T cells to ensure the survival of tumor cells.Treg cells support their proliferative and suppressive functions by metabolizing lactate. To further verify the relationship between the two, the researchers targeted a gene called MCT1, which encodes a lactate transporter in Treg cells, and then combined MCT1 knockout or drug inhibition with immunotherapy.The findings suggest that preventing lactate uptake by Treg cells in the tumor microenvironment slows tumor growth and increases response to immunotherapy.Greg DelgoffeSaid: "Cancer cells are very smart. The tumor microenvironment will not only starve the effector T cells that harm them, but also feed the Treg cells that protect them. This study shows that inhibiting the uptake of lactic acid starves Treg cells. When Treg cells cannot be maintained by the tumor, effector T cells will come in and kill the cancer cells." Stop.Lactate uptake by Treg cells in the tumor microenvironment slows tumor growth and increases response to immunotherapy. In summary, this study shows us the "insidiousness" of cancer cells: the tumor microenvironment not only hinders the killing function of effector T cells, but also "tricks" Treg cells to further inhibit effector T cells, thereby promoting the survival of cancer cells.Not only that, this study also explains to a certain extent the insensitivity of some cancer patients to immunotherapy. In the future, perhaps we can enhance the effectiveness of immunotherapy by inhibiting lactate metabolism-related genes, such as MCT1, so that immunotherapy can truly benefit the majority of cancer patients!References: https://www.nature.com/articles/s41586-020-03045-2https://www.genengnews.com/news/preventing-regulatory-t-cells-from-feeding-on-lactate-slows-tumor-growth-and-increases-response-to-immunotherapy/ 倒刃胃澄头泵故掷逼骋胃匆蔚认啡